For years, Merck & Co. has had an upper hand over its chief cancer drug competitor Bristol Myers Squibb. In March, however, Bristol Myers beat …
Dive Brief: Merck has tapped a former executive, Joseph Romanelli, to run the company’s pharmaceutical business in markets outside the U.S. after restructuring its human …
An immunotherapy from Merck & Co. is the latest drug of its kind to slow the return of lung cancer in clinical testing, though mixed …
Dive Brief: The Food and Drug Administration has rejected Merck & Co’s experimental drug for chronic cough, issuing the company a complete response letter for …
The second day of the J.P. Morgan Healthcare Conference, much like the first, didn’t include the type of market-moving acquisitions or announcements that might break …
Paxlovid and molnupiravir are the first oral treatments for COVID-19, potentially valuable new tools as the fast-spreading omicron variant fuels a sharp surge in cases …
Currently, the world’s best-selling HIV medications are made up of at least three “active ingredients.” But recent years have seen increasing interest in treatments that …
Approval of Keytruda in this setting comes about six months after Merck revealed early results from a study called Keynote-564, which showed the immunotherapy could …
Merck is now in a race with Pfizer to capture the upside of COVID-19 pills, which could soon play an outsized role in the next …
U.K. regulators have once again moved faster than the Food and Drug Administration to approve a new medicine for COVID-19. The UK’s Medicines and Healthcare …
Merck’s pill has the potential to alter the course of the pandemic. Earlier this month, the company and partner Ridgeback Biotherapeutics released data showing molnupiravir …
This is the first time government advisers have recommended routine use of a pneumococcal vaccine for certain risk groups within the 19-64 age bracket, a …
The Gates Foundation hopes to reduce the gap in time between when wealthy countries and lower-income nations get access to needed medicines like molnupiravir. The …
Merck’s Keytruda is the dominant cancer immunotherapy and, of the seven of its type that are approved, the only that’s cleared for use in cervical …
Merck’s filing comes less than two weeks after the drugmaker showed molnupiravir lowered the risk of hospitalization or death by roughly 50% in a Phase …
Insurers Centene and Humana have sued Merck & Co., alleging the drugmaker’s “monopolistic scheme” delayed generic versions of its blockbuster cholesterol drug Zetia from coming …
The FDA has been under pressure to review the status of drugs granted accelerated approvals based on early data, as in some cases confirmatory trials …
Peloton was one of a handful of cancer-focused biotech companies acquired since 2018 by Merck, which has sought to complement its top-selling immunotherapy Keytruda with …
Melanoma is one of the fastest growing malignant cancers in China, increasing at an annual rate of 3-5 percent, which makes it one of the …
China has more than 114 million people living with diabetes, the largest number of any country in the world Global drug giant, Merck signed an …
